Switching between raltegravir resistance pathways analyzed by deep sequencing

Objective:Our objective was to analyze the pathways leading to resistance of HIV to the integrase (IN) inhibitor raltegravir (RAL). Design:Three HIV-infected individuals exhibiting RAL resistance pathway switching were characterized using longitudinal analysis of viral samples from plasma. Methods:454/Roche pyrosequencing was used to generate approximately 74 000 sequence reads from the integrase coding region. Effects of error were controlled by denoising with Pyronoise, and by comparison to approximately 142 000 control reads from HIVNL4-3. Viral lineages were modeled quantitatively using viral serial pathway analysis (vSPA). Results:All three patients showed transitions from the N155H pathway to the Q148H/G140S pathway. Analysis with vSPA revealed complex pathways to the final genotype, probably involving both de-novo mutation and recombination. No reads contained both the N155H and Q148H drug resistance mutations (DRMs), indicating that the double mutant is not a prominent intermediate, consistent with low fitness. To characterize possible drug-resistant variants circulating prior to therapy, we sequenced approximately 70 000 reads from samples collected prior to initiating treatment. Although some preexisting drug-resistant variants were detected, N155H, the first major DRM present after initiating RAL therapy, was not detected. Conclusion:The main DRMs are present at very low levels if at all prior to initiating therapy. We also outline general methods for deep sequence analysis of DRMs in longitudinal HIV samples.

[1]  C. Charpentier,et al.  Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure , 2009, Antimicrobial Agents and Chemotherapy.

[2]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[3]  Deenan Pillay,et al.  Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase , 2008, Journal of Virology.

[4]  M. Ronaghi,et al.  Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.

[5]  Niko Beerenwinkel,et al.  Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies , 2010, Nucleic acids research.

[6]  J Cairns,et al.  Cold spring harbor. , 1991, Science.

[7]  Christos J. Petropoulos,et al.  Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways , 2009, Journal of Virology.

[8]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[9]  Susan M. Huse,et al.  Accuracy and quality of massively parallel DNA pyrosequencing , 2007, Genome Biology.

[10]  R. Paredes,et al.  Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. , 2010, Antiviral research.

[11]  C. Quince,et al.  Accurate determination of microbial diversity from 454 pyrosequencing data , 2009, Nature Methods.

[12]  Hiroshi Tanaka,et al.  Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA , 2009, BMC Bioinformatics.

[13]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[14]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[15]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[16]  Kevin Dieckhaus,et al.  Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use , 2009, PloS one.

[17]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[19]  Volker Roth,et al.  Deep Sequencing of a Genetically Heterogeneous Sample: Local Haplotype Reconstruction and Read Error Correction , 2009, RECOMB.

[20]  Emily S. Charlson,et al.  Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIxS) specifications , 2011, Nature Biotechnology.

[21]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[22]  C. Charpentier,et al.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy * , 2008, HIV medicine.

[23]  Amy S. Espeseth,et al.  Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. Bushman,et al.  DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations , 2007, Nucleic acids research.

[25]  Lior Pachter,et al.  Viral Population Estimation Using Pyrosequencing , 2007, PLoS Comput. Biol..

[26]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.